Interestingly, Rac1 inhibition displayed selective activity on patient-derived leukemic cells having no cytotoxic effect on normal monocytic and lymphocytic cells, representing a promising pharmacological and selective compound for the treatment of hematological malignancies. This evidence concerns the gene RAC1 and hematologic disorder.